Skip to content 
Research teams evaluating FOXO4-DRI procurement should review compound identity, RUO labeling, and analytical records. FOXO4-DRI appears in cellular senescence literature as a D-retro-inverso peptide studied in FOXO4-p53 interaction models [3], [4], [5]. This guide covers literature interpretation, certificate-of-analysis review, and comparison of lot-level records. The supplied material is not intended for personal, therapeutic, or clinical use.
- FOXO4-DRI Peptide is best evaluated as a research peptide within cellular senescence research, with attention to FOXO4, p53, apoptosis research, and senescent cell models.
- Published literature can explain research context, but it should not be converted into product claims or intended-use statements for RUO materials.
- COA review should focus on compound name, lot number, purity method, identity testing, test date, and batch-specific consistency.
- HPLC can support peptide purity review, while LC-MS and mass spectrometry can support identity verification when paired with suitable analytical records [12], [15].
- D-retro-inverso design is a peptide chemistry concept involving reversed sequence direction and D-amino acid stereochemistry, which is relevant to peptide stability research [5].
- The supplied material is for laboratory research, not personal or clinical use.
- Research buyers should save the label, COA, lot record, storage documentation, and product-page record used during procurement review.
Fast Answer: What Should Researchers Check Before They Buy FOXO4-DRI Peptide for Research?
Researchers looking to buy FOXO4-DRI Peptide for research should first verify RUO labeling, batch-specific COA data, peptide identity records, and analytical testing support. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. The safest commercial research review starts with documentation, not claims.
FOXO4-DRI is a specific research construct
Before you buy FOXO4-DRI peptide for research, verify that the record identifies the D-retro-inverso construct rather than the native FOXO4 protein. Compare the sequence, identity analysis, and lot-specific certificate of analysis with the material listed.
That distinction matters. FOXO4-DRI is discussed in published senescence research as a synthetic peptide connected to FOXO4-p53 interaction models, but that literature does not define a consumer purpose for an RUO research material [3], [4].
What Documentation Should Be Reviewed First?
Start with the product name, lot number, label language, and batch-specific COA. A certificate of analysis should identify what was tested, which analytical method was used, when the test was performed, and whether the lot record matches the product listing.
For a research peptide, the strongest documentation set usually combines identity information, purity information, lot traceability, and storage records. Analytical validation guidance treats identity, purity, assay, and impurity testing as distinct analytical purposes, so a single number should not be read as the whole documentation story [12].
Why RUO Labeling Should Come Before Procurement
RUO labeling keeps procurement review aligned with research purposes.
FOXO4-DRI Peptide Research-Use-Only Context
FOXO4-DRI Peptide is supplied for laboratory research only. It is not intended for personal, therapeutic, diagnostic, clinical, veterinary, wellness, cosmetic, or fitness purposes.
Official RUO labeling rules in the IVD context show why research-only wording must stay tied to intended research settings and separate from diagnostic claims [18]. That regulatory example is not a product classification for this peptide; it is a useful documentation principle.
What Does Research Use Only Mean for This Material?
Evaluate FOXO4-DRI as a laboratory material by reviewing compound identity, published research context, and lot-specific documentation before procurement.
Published literature is not product-use guidance and does not establish that a Pure Lab Peptides research material is approved, cleared, or intended for any non-research context.
Which Documentation Can Researchers Check?
Check the COA, purity method, LC-MS identity support, lot number, storage documentation, and RUO label consistency.
Published studies may discuss apoptosis in senescent cells [3], [17]. Those findings remain specific to the experimental models and do not establish effects of a supplied research-use-only material.
What Is FOXO4-DRI in Cellular Senescence Research?
FOXO4-DRI is discussed in cellular senescence research as a D-retro-inverso peptide related to FOXO4 and p53 interaction models. The original research literature examined FOXO4 as part of senescent cell viability models and evaluated a FOXO4-derived D-retro-inverso peptide in that research setting [3].
Cellular senescence itself is a complex cell state, and expert consensus literature emphasizes that senescence requires careful marker selection and model-specific interpretation [6].
FOXO4-DRI Peptide Identity and Research Classification
FOXO4 is a forkhead box protein listed in UniProt as a human transcription factor, and the reviewed UniProt entry for FOXO4 identifies the protein as 505 amino acids in length [1]. p53, encoded by TP53, is also listed in UniProt as a transcription factor involved in cell-cycle and apoptosis-related contexts [2].
FOXO4-DRI research examines molecular binding involving FOXO4 and p53. For procurement, confirm that the material’s name, documentation, and analytical records align with the compound being evaluated.
How D-Retro-Inverso Design Relates to Peptide Stability
A D-retro-inverso peptide uses D-amino acid stereochemistry with sequence reversal to mimic side-chain orientation while changing the peptide backbone arrangement [5]. Reviews of retro-inverso peptides describe this design as a peptide chemistry strategy often studied for stability and molecular recognition questions [5].
For FOXO4-DRI documentation, that means buyers should look for clear identity records.
Where FOXO4 and p53 Fit in Senescence Literature
FOXO4 and p53 appear together in FOXO4-DRI research because published studies have examined the FOXO4-p53 interaction in senescent cell models [3], [4]. Structural work published in 2025 reported solution NMR models involving the p53 transactivation domain, FOXO4, and FOXO4-DRI, which adds molecular binding context to earlier literature [4].
Compound Identity Details for Product Documentation
Product documentation should make the compound easy to verify across records. The product listing, COA, label, lot number, and analytical test record should all point to the same FOXO4-DRI Peptide identity.
Documentation review is especially important for synthetic peptide materials because peptide quality discussions often involve identity, purity, impurities, analytical method, reference standards, and stability records [15]. A clean product-page review keeps each of those categories separate.
Why Molecular Weight Matters for Peptide Records
Molecular weight is one identity-related attribute used in peptide documentation. LC-MS or other mass spectrometry records can support identity review by connecting the observed mass data to the expected peptide identity when the method and batch record are clear [12], [15].
Molecular weight alone is not the same as complete documentation. It should be evaluated alongside peptide name, sequence documentation when available, lot number, COA, and analytical method.
What Amino Acid Sequence Review Adds to Documentation
Amino acid sequence review can add another identity layer when sequence information is verified from a trusted source or supplier record. For synthetic peptide documentation, sequence-level information is most useful when it connects directly to a batch-specific COA and identity testing record.
How Does Published Literature Frame FOXO4-DRI Peptide Research?
Published literature frames FOXO4-DRI Peptide primarily through cellular senescence, FOXO4-p53 interaction, and apoptosis research models [3], [4].
What In Vitro Models Can Clarify
In vitro models can clarify how a compound behaves in defined cell systems. For FOXO4-DRI, literature has examined senescent fibroblast, Leydig-cell, chondrocyte, and endothelial-cell model contexts [3], [10], [11], [19].
That evidence remains model-specific. It supports research context, not product positioning outside RUO documentation.
How Senescent Cell Models Appear in Literature
Senescent cell models are often characterized using multiple markers rather than a single feature. Consensus literature describes cellular senescence as a state with growth arrest, stress-response features, and diverse molecular markers that vary by context [6].
FOXO4-DRI literature often discusses senescent cell models together with p53, p21, p16, SASP markers, and SA-β-Galactosidase assays [3], [6], [8], [9]. Those markers help interpret research models, but no marker alone makes a broad product claim.
Why Preclinical Findings Require Careful Interpretation
Preclinical literature can identify research hypotheses, model-specific observations, and pathway questions. It cannot be treated as product-use guidance for RUO materials.
| Research Area | What Literature Examines | Evidence Type | RUO Interpretation |
|---|---|---|---|
| FOXO4-p53 interaction | FOXO4 and p53 binding context in senescence models [3], [4] | Mechanistic and structural literature | Useful for pathway context, not a product claim |
| Cellular senescence markers | p16, p21, SA-β-Galactosidase, and SASP patterns [6], [7], [8], [9] | Review, assay, and cell-model literature | Useful for research interpretation; marker choice is model-specific |
| Chondrocyte model literature | Senescence-related markers in expanded chondrocyte models [10] | In vitro research | Relevant as a model example, not an intended-use statement |
| Endothelial-cell model literature | P53 signaling pathway context in FOXO4-DRI senescence research [19] | Recent cell-model literature | Relevant as evolving literature context, not product positioning |
| Analytical verification | Identity, purity, and method records for peptide materials [12], [15] | Analytical and standards literature | Relevant for COA review and procurement documentation |
Where Do FOXO4, p53, and Apoptosis Fit in Pathway Context?
FOXO4, p53, and apoptosis appear together because the literature has examined how FOXO4-p53 interaction models relate to senescent cell viability and programmed cell death research [3], [4], [17]. Apoptosis is generally defined as a programmed cell death process with characteristic biochemical and morphological features [17].
How Is the FOXO4 Transcription Factor Discussed?
FOXO4 is discussed as a forkhead box transcription factor. UniProt describes FOXO4 as involved in insulin signaling pathway regulation and transcriptional activation at insulin-response elements [1].
That database-level identity helps define the research entity. It does not replace batch-specific FOXO4-DRI Peptide documentation.
What Molecular Binding Context Adds to Review
Molecular binding context helps explain why FOXO4 and p53 appear together in the literature. The 2025 structural study reported p53 transactivation-domain complexes involving FOXO4 and FOXO4-DRI, which supports a more detailed research map of this interaction [4].
For procurement review, this is background context. The actionable review items remain COA, identity testing, lot traceability, and RUO labeling.
Senescence-Associated Secretory Phenotype and Cell Model Coverage
The senescence-associated secretory phenotype, often shortened to SASP, is part of cellular senescence literature. Coppé and colleagues described SASP patterns involving secreted factors in senescence models, and later reviews continue to treat SASP as a core but context-sensitive feature of senescence research [7], [6].
What Do SASP Markers Add to Literature Review?
SASP markers help researchers organize literature around secretory profiles, inflammatory signaling context, and cell-model differences [7]. These markers can clarify what a paper measured and how the model was interpreted.
SASP markers do not establish a specific biological outcome for the supplied research material.
How Does SA-β-Galactosidase Appear in Cellular Senescence Models?
SA-β-Galactosidase is a widely used senescence-associated assay marker first described as detectable at pH 6 in senescent cells in culture [8]. Later senescence literature continues to discuss SA-β-Galactosidase as a useful but context-dependent marker [6].
This is a good example of why marker interpretation requires caution. A marker can support model characterization, but it does not define every senescent cell state by itself.
Why Fibroblast and Chondrocyte Models Need Separation
Fibroblast and chondrocyte models should be interpreted separately because cell type, culture conditions, marker selection, and endpoint design can change what the literature shows. FOXO4-DRI has been examined in fibroblast-related senescence research and in expanded chondrocyte model literature [3], [10].
How Should Research Literature Stay Separate From Product Claims?
The key research boundary is simple: literature context is not product positioning.
Model-specific findings do not establish clinical outcomes or effects of the supplied material.
Why Should Study Findings Stay Separate From Product Claims?
Study findings have methods, limitations, controls, and model conditions. Product pages have listing records, labels, COAs, and procurement documentation.
Why Does Certificate of Analysis Review Matter for FOXO4-DRI?
A certificate of analysis matters because it gives laboratory buyers a batch-level record to compare against the product listing. For FOXO4-DRI Peptide, COA review should focus on whether the compound name, lot number, purity method, identity method, test date, and supplier record align.
Analytical validation sources treat identity and purity as separate analytical purposes, so a COA should not be reduced to a single purity percentage [12], [14]. Strong documentation shows how the result was generated.
What Should a Certificate of Analysis Confirm?
A COA should confirm the tested material, lot identifier, analytical method, test result, testing date, and reporting source. For peptide materials, reference-standard and analytical literature also emphasizes the importance of characterization, stability studies, and analytical testing for quality-related records [15].
A COA should be batch-specific whenever possible. If the COA cannot be matched to the product lot, it is less useful for technical procurement review.
How Batch-Specific Documentation Supports Review
Batch-specific documentation lets research teams connect a product listing to a specific tested lot. That matters because peptide identity and purity are analytical questions, not general brand statements.
Batch records also support reproducibility in laboratory documentation. A lab record that includes lot number, COA date, storage record, and supplier documentation is easier to audit than a general product page snapshot.
Where COA Review Fits Before Teams Buy FOXO4-DRI Peptide for Research
COA review should come before catalog selection is finalized. Teams evaluating where to buy FOXO4-DRI Peptide for research should compare the product listing, COA, label, and lot record before treating the material as procurement-ready.
This is a documentation workflow, not a claim review. The goal is to confirm that the research material is clearly identified and appropriately documented.
Analytical Testing Workflow for FOXO4-DRI Peptide
Analytical testing helps support peptide identity and purity review. HPLC, LC-MS, mass spectrometry, reference standards, and validated analytical procedures each answer different documentation questions [12], [13], [15].
A practical lab-test verification workflow can include:
- Verify that the compound name, lot number, and label match across records.
- Review the batch-specific certificate of analysis.
- Check whether the purity testing method is listed.
- Confirm whether identity testing is supported by LC-MS, mass spectrometry, or another suitable analytical method.
- Review chromatogram or mass data when available.
- Check the COA date and reporting source.
- Record storage and handling requirements in a laboratory documentation file.
How Does HPLC Support Peptide Purity Review?
HPLC supports peptide purity review by separating detected components and reporting chromatographic data. Analytical guidance treats purity and impurity testing as common analytical procedure purposes, which is why the method and result should both appear in documentation [12].
For peptide research materials, HPLC purity should be read as one part of the record. It does not, by itself, prove complete identity.
How Does LC-MS Support Peptide Identity Verification?
LC-MS combines chromatographic separation with mass spectrometry data. For peptide documentation, mass spectrometry can support identity review by comparing observed mass-related data with expected peptide characteristics when the method is suitable and the record is batch-specific [12], [15].
This is why HPLC and LC-MS work best as complementary documentation signals. One helps with purity review; the other can help with identity confirmation.
Lot Traceability and Supplier Documentation Standards
Lot traceability connects the product listing to the actual tested batch. That connection matters because research procurement depends on records that can be matched, saved, and reviewed later.
Supplier documentation should be internally consistent. The lot number on the label should match the COA, and the COA should match the product listing used by the laboratory buyer.
Why Do Lot Numbers Matter in Research Procurement?
Lot numbers matter because they make documentation specific. Without lot-level matching, a COA may describe a similar material without confirming the exact research material under review.
Lot records also support reproducibility. If a lab team later revisits a study record, the lot number helps connect the material to the correct COA and storage record.
What Should Research Buyers Compare Across Records?
Research buyers should compare compound name, lot number, purity result, identity method, COA date, label language, storage information, and supplier documentation. Analytical procedure guidance emphasizes that method documentation supports quality-related records, including identity and purity data [14].
The review should be practical. If the records do not align, the documentation should be clarified before procurement.
Labeling, Storage Records, and Handling Documentation
Labeling and storage records help keep research materials traceable after procurement. For FOXO4-DRI Peptide, the label should clearly indicate research-use-only status and match the lot documentation.
Storage documentation is also relevant when a peptide is listed as lyophilized. Stability guidance describes how quality can vary with environmental factors such as temperature, humidity, and light, which is why storage records belong in laboratory documentation [16].
How Should RUO Labeling Appear on Product Records?
RUO labeling should be clear, visible, and consistent across the product page, label, and supporting records. The same research-only framing should appear in product documentation and procurement notes.
A clear label does not replace analytical testing. It supports the intended research boundary while the COA and testing records support identity and purity review.
What Can Storage Documentation Clarify?
Storage documentation clarifies the recorded conditions associated with the research material. It can include temperature range, light sensitivity notes, desiccation considerations, and internal lab record entries, depending on the supplier record and institutional procedures.
The purpose is traceability. Storage documentation helps research teams preserve a clear record of how the material was received and maintained in a laboratory setting.
Common Misunderstandings About FOXO4-DRI Research Pages
The following misunderstandings are the most important to correct.
Why Are Literature Mentions Not Product Claims?
A literature mention means a study examined a research question. It does not mean a product page can claim the same finding for a listed RUO material.
For example, a paper may discuss FOXO4-p53 interaction models, senescent cell markers, or apoptosis research [3], [4], [17].
What Should Researchers Treat as Context Only?
Researchers should treat pathway descriptions, model-specific findings, and senescence-marker discussions as context only. FOXO4, p53, SASP, SA-β-Galactosidase, p16, p21, and apoptosis are useful scientific terms, but they do not replace product documentation [1], [2], [6], [7], [8], [9], [17].
A second common misunderstanding is that a purity value proves everything. It does not. Identity support, lot matching, method details, and COA source all matter [12], [15].
Research Procurement Checklist for FOXO4-DRI Peptide
Research procurement should be documentation-first. A clear checklist helps laboratory buyers evaluate FOXO4-DRI Peptide without drifting into consumer-style claims.
Use this checklist before final catalog selection:
- Verify that the compound is labeled for research use only.
- Review the batch-specific certificate of analysis.
- Confirm that purity data are supported by an analytical testing method.
- Check that the lot number on the COA matches the product documentation.
- Compare compound name, molecular weight record, and identity documentation across records.
- Assess whether the product page avoids personal-use, therapeutic-use, or product-performance claims.
- Document storage and handling conditions in a laboratory record.
- Save the product-page record, COA, label, and supplier documentation used for procurement review.
What Should Researchers Review Before Catalog Selection?
Researchers should review the product page, COA, lot number, analytical testing records, label language, and storage documentation. For FOXO4-DRI Peptide, literature context can guide what the compound is, but documentation confirms what the supplier record supports.
A procurement record should answer four questions: What is the compound? Which lot is documented? How were purity and identity assessed? Is the material clearly labeled for laboratory research only?
Documentation Before FOXO4-DRI Procurement
Before laboratory procurement, review the FOXO4-DRI identity record, lot-specific analytical results, and supporting documentation.
What Final Records Should Lab Teams Save?
Lab teams should save the product listing, COA, label record, lot number, storage information, and any available analytical testing documentation. If the record includes HPLC or LC-MS data, that information should be saved with the batch file.
Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.
Review the product-page documentation, COA details, analytical testing support, and RUO labeling before evaluating FOXO4-DRI Peptide for laboratory research procurement.
FAQs
What is FOXO4-DRI Peptide in research literature?
FOXO4-DRI Peptide is a research peptide discussed in cellular senescence literature as a FOXO4 D-retro-inverso peptide. Published research connects it to FOXO4 protein, p53 protein, FOXO4 binding, and model-specific pathway research [3], [4].
What experimental models are discussed in FOXO4-DRI research?
FOXO4-DRI research is discussed in model-specific literature involving senescent cell systems, including fibroblast and chondrocyte research contexts [3], [10]. These models help researchers study cellular senescence markers, gene expression patterns, and pathway questions. Findings should remain tied to the experimental model and should not be converted into broad product claims.
What are senescent cells, and why are they studied alongside FOXO4-DRI?
Senescent cells are studied because cellular senescence is a research state involving growth arrest, stress-response features, and marker patterns that vary by model [6]. FOXO4-DRI appears in literature connected to regulation of cellular senescence and accumulation of senescent cells. Researchers should interpret those topics through published literature, model design, and RUO documentation.
What pathway context is associated with FOXO4-DRI?
FOXO4-DRI pathway context centers on FOXO4, p53, molecular binding, apoptosis research, and cell signaling models [3], [4]. FOXO4 is a transcription factor, while p53 is often discussed in cell-cycle and programmed cell death literature [1], [2].
What should researchers consider before they buy FOXO4-DRI Peptide for research?
Researchers should consider compound characterization, COA availability, analytical testing records, lot traceability, and RUO labeling before they buy FOXO4-DRI Peptide for research. Documentation should connect the product listing, batch record, peptide identity, and purity review. If records do not align, the documentation should be clarified before procurement review.
How can freeze drying and documentation relate to FOXO4-DRI Peptide records?
Freeze drying may appear in peptide documentation as part of how a laboratory material is listed or stored. For FOXO4-DRI Peptide records, researchers should focus on label consistency, storage documentation, COA details, and batch-specific files.
Researchers Cited in This Guide
The researchers listed below are cited for relevant published work. Their inclusion does not imply that they wrote, reviewed, or endorsed this guide or Pure Lab Peptides products.
Peter L. J. de Keizer
Author profile: University Medical Center Utrecht Profile
Peter L. J. de Keizer’s publications address cellular senescence, FOXO4-p53 interactions, and FOXO4-DRI research models. The selected work provides context for interpreting compound identity and model-specific pathway findings.
Selected publications:
- A peer-reviewed study relevant to FOXO4-DRI research models — Cell, 2017. DOI: 10.1016/j.cell.2017.02.031. PMID: [28340339]
- A structural publication relevant to FOXO4, p53, and FOXO4-DRI research context — Nature Communications, 2025. DOI: 10.1038/s41467-025-60844-9
Tobias Madl
Author profile: Medical University of Graz Profile
Tobias Madl’s publications address molecular biology and biochemistry relevant to FOXO4-p53 interactions, including disordered protein interactions and structural research involving FOXO4-DRI.
Selected publications:
- Regulation of cellular senescence via the FOXO4-p53 axis — FEBS Letters, 2018. DOI: 10.1002/1873-3468.13057. PMID: [29683489]
- A structural publication relevant to FOXO4, p53, and FOXO4-DRI research context — Nature Communications, 2025. DOI: 10.1038/s41467-025-60844-9
REFERENCES
- UniProt Consortium. FOXO4 — Forkhead box protein O4, Homo sapiens. UniProtKB. Reviewed entry P98177.
- UniProt Consortium. TP53 — Cellular tumor antigen p53, Homo sapiens. UniProtKB. Reviewed entry P04637.
- Baar MP, Brandt RMC, Putavet DA, et al. FOXO4-DRI and senescent-cell apoptosis model research. Cell. 2017. DOI: 10.1016/j.cell.2017.02.031. PMID: 28340339.
- Bourgeois B, et al. p53 transactivation-domain interaction with FOXO4 and FOXO4-DRI. Nature Communications. 2025. DOI: 10.1038/s41467-025-60844-9.
- Doti N, Mardirossian M, Sandomenico A, Ruvo M, Caporale A. Recent Applications of Retro-Inverso Peptides. International Journal of Molecular Sciences. 2021. PMID: 34445382.
- Gorgoulis V, Adams PD, Alimonti A, et al. Cellular Senescence: Defining a Path Forward. Cell. 2019. DOI: 10.1016/j.cell.2019.10.005. PMID: 31675495.
- Coppé JP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotype research. PLOS Biology. 2008. DOI: 10.1371/journal.pbio.0060301. PMID: 19053174.
- Dimri GP, Lee X, Basile G, et al. SA-β-Galactosidase marker research in senescent cells. Proceedings of the National Academy of Sciences. 1995. PMID: 7568133.
- Wagner KD, Wagner N. Senescence markers p16, p14ARF/p19ARF, and p21. Cells. 2022. PMID: 35741095.
- Huang Y, He Y, Makarcyzk MJ, Lin H. FOXO4-DRI research in expanded chondrocyte models. Frontiers in Bioengineering and Biotechnology. 2021. DOI: 10.3389/fbioe.2021.677576. PMID: 33996787.
- Zhang C, Xie Y, Chen H, et al. FOXO4-DRI research in Leydig-cell senescence models. Aging. 2020. PMID: 31959736.
- U.S. Food and Drug Administration. Q2(R2) Validation of Analytical Procedures. FDA Guidance page. 2024.
- U.S. Food and Drug Administration. Q14 Analytical Procedure Development. FDA Guidance page. 2024.
- U.S. Food and Drug Administration. Analytical Procedures and Methods Validation for Drugs and Biologics. FDA Guidance page. 2015.
- McCarthy D, et al. Reference standards supporting synthetic peptide quality. Pharmaceutical Research. 2023. PMID: 36949371.
- U.S. Food and Drug Administration. Q1A(R2) Stability Testing of New Drug Substances and Products. FDA Guidance page. 2018.
- Elmore S. Apoptosis: A Review of Programmed Cell Death. Toxicologic Pathology. 2007. PMID: 17562483.
- Electronic Code of Federal Regulations. 21 CFR 809.10 labeling statement for research-use-only IVD products. eCFR. Current as accessed.
- Hu Z, Li F, Hu C, et al. FOXO4-DRI and P53 signaling in endothelial-cell senescence research. Frontiers in Bioengineering and Biotechnology. 2026. PMID: 41625068.
Research Disclaimer
This material is supplied strictly for in vitro laboratory research and is not for human or veterinary use. Published studies describe specific experimental materials, models, and methods; they do not establish the safety, efficacy, or suitability of this catalog product for non-research use. Review the original publications and the lot-specific analytical documentation independently.
There are no reviews yet.